AcelRx Pharma (ACRX) – Company Press Releases
-
AcelRx Announces Rebranding With Name Change to Talphera, Inc.
-
AcelRx Pharmaceuticals Announces Publication of Study Evaluating Anticoagulation Practices for Continuous Renal Replacement Therapy in the United States
-
AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Update
-
AcelRx to Host KOL Panel Discussion on Current Anticoagulant Use in Dialysis and the Upcoming Niyad™ Clinical Study
-
AcelRx to Host Third Quarter 2023 Financial Results Call and Webcast on November 8, 2023
-
AcelRx Receives IDE Approval for Niyad and Advances to a Single Registration Study
-
AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Annual Investment Conference
-
AcelRx Reports Second Quarter 2023 Financial Results and Provides Corporate Update
-
AcelRx to Host Second Quarter 2023 Financial Results Call and Webcast on August 10, 2023
-
AcelRx Pharmaceuticals Announces Closing of Previously Announced Private Placement Priced At-The-Market Under Nasdaq Rules
-
AcelRx Pharmaceuticals Announces $10 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules
-
AcelRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
-
AcelRx to Host First Quarter 2023 Financial Results Call and Webcast on May 10, 2023
-
AcelRx Pharmaceuticals Announces Closing of Divestment of DSUVIA® to Alora Pharmaceuticals
-
AcelRx Pharmaceuticals Reports Full Year and Fourth Quarter 2022 Financial Results and Provides Corporate Update
-
AcelRx to Host Full Year and Fourth Quarter 2022 Financial Results Call and Webcast on March 30, 2023
-
AcelRx Pharmaceuticals Announces Divestment of DSUVIA® to Alora Pharmaceuticals
-
AcelRx Pharmaceuticals Announces Peer-Reviewed Publication On the Use of DSUVIA® For In-Office Rhinology Procedures
-
AcelRx Announces $7.5 Million Registered Direct Offering of Common Stock and Warrants to Purchase Common Stock
-
AcelRx Pharmaceuticals Announces European Peer-Reviewed Publication Supporting the Benefits of Sublingual Sufentanil Tablets For Post-Operative Pain Management in the Journal of Clinical Medicine
-
AcelRx Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
-
AcelRx to Host Third Quarter 2022 Financial Results Call and Webcast on November 14, 2022
-
AcelRx Pharmaceuticals Announces Presentation of a Large Cohort of Complex Plastic Surgery Procedures Performed with DSUVIA at Plastic Surgery The Meeting 2022
-
AcelRx Pharmaceuticals Announces the European Launch of DZUVEO by its Partner, Aguettant
-
AcelRx Pharmaceuticals Announces Presentation of Investigator-Initiated Trial Results Comparing AcelRx's Sufentanil Sublingual Tablet (SST) Versus Intravenous Opioids for Postoperative Pain at the ANE
-
AcelRx Pharmaceuticals Announces Reverse Stock Split
-
AcelRx Pharmaceuticals Announces ANESTHESIOLOGY® 2022 Annual Meeting Presentation on DSUVIA® for Battlefield Analgesia by the Uniformed Services University of the Health Sciences
-
AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Annual Investment Conference
-
AcelRx Pharmaceuticals Announces a Second Abstract on DSUVIA® Accepted for Presentation at the ANESTHESIOLOGY® 2022 Annual Meeting
-
AcelRx Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
-
AcelRx Pharmaceuticals Announces Abstract Acceptance for Podium Presentation at Plastic Surgery: The Meeting 2022
-
AcelRx Pharmaceuticals Announces Abstract Acceptance for Podium Presentation at the ANESTHESIOLOGY® 2022 Annual Meeting
-
AcelRx to Host Second Quarter 2022 Financial Results Call and Webcast on August 11, 2022
-
AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Global Investment Conference
-
AcelRx Pharmaceuticals Provides Update on Reduced FDA REMS Requirements Related to DSUVIA®
-
AcelRx Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
-
AcelRx Pharmaceuticals Announces Publication of Results from an Investigator-Initiated Trial on Sufentanil Sublingual Tablet (SST) Compared to Standard Intravenous Opioids during Plastic Surgery Proce
-
AcelRx to Host First Quarter 2022 Financial Results Call and Webcast on May 16, 2022
-
AcelRx Hosting Key Opinion Leader Webinar on Niyad™ Nafamostat Program
-
Minimal Side Effects and Short Recovery Time Reported for DSUVIA®-Treated Patients: Plastic Surgery Podium Presentation at The Aesthetic Meeting 2022
-
AcelRx Pharmaceuticals Announces Upcoming Podium Presentation on Use of DSUVIA® for Plastic Surgery Procedures at The Aesthetic Meeting 2022
-
AcelRx Pharmaceuticals Announces Publication of Results from a Clinical Study Assessing Use of Sufentanil Sublingual Tablet for Painful Radiofrequency Microneedling Procedures
-
AcelRx Pharmaceuticals Announces Publication of Clinical Data Finding Potential Benefits of Nafamostat Compared to Regional Citrate for Anticoagulation of the Dialysis Circuit
-
AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results
-
AcelRx to Host Fourth Quarter and Full Year 2021 Financial Results Call and Webcast on March 10, 2022
-
AcelRx Pharmaceuticals Announces Publication of Clinical Data on the Use of Sufentanil Sublingual Tablet during Awake Plastic Surgery Procedures
-
AcelRx Pharmaceuticals Announces Publication of an Article Highlighting the Utility of the Sufentanil Sublingual Tablet in Pain Medicine Procedures
-
AcelRx Pharmaceuticals Announces Publication of an Editorial by an Internationally Recognized Leader in Opioid-Sparing Surgery Highlighting the Potential Advantages of the Sufentanil Sublingual Tablet
-
AcelRx Pharmaceuticals Announces the Closing of its Acquisition of Lowell Therapeutics
-
AcelRx Pharmaceuticals Announces Publication of Clinical Data Showing Reduced Hospital Length of Stay and Reduced Opioid Utilization with Use of Sublingual Sufentanil in Total Joint Replacement Surger
Back to ACRX Stock Lookup
